MAPT and dementia: Increased FCN2 levels in the [18F]-flutemetamol PET positive group were observed by logistic regression (β = 0.580, P < 0.05, Supplementary Table 7), replicating the relationship with CSF Tau/Aβ42 observed in the Amsterdam Dementia Cohort.